Abstract
Due to heterogeneity in presentation and outcome, patients with metastatic disease cannot be considered a single group. The timing, location and combinations of recurrences determine the feasibility of treatment of the individual patient in an era in which the options for local and systemic treatment have expanded. Studies investigating this complexity are hampered by the lack of both large cohorts and adequate methods.
In a well-defined cohort of rectal cancer patients from a randomized clinical trial, with long standardized follow-up, we applied spatial projection models derived from population ecology to overcome the complexity problem. We describe the recurrence patterns in detail and performed stochastic simulation experiments resulting in 1.5 million evaluable patients. The risk of subsequent recurrences was dependent on the presentation of the first recurrent event and decreased with increasing recurrence-free interval. The risk of local recurrence for the median patient (65.8 years, pT3 adenocarcinoma) was threefold increased after the development of rare metastases. The risk of development of rare metastases was increased after the development of other extrahepatic metastases.
Our cross-disciplinary approach delivers insights allowing for the development of personalized strategies for (local) treatment of recurrent disease, as well as for surveillance strategies that may potentially impact large patient cohorts. In this proofof-principle study we demonstrate the feasibility of spatial projection models for cancer research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The clinical trial was funded by the Dutch Cancer Society (CKVO 95-04), the Dutch National Health Council (OWG 97/026) and the Swedish Cancer Society
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Leiden University Medical Center Ethical Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: no financial support was provided for this study
Conflict of interest: The authors declare no potential conflicts of interest
Translational relevance Even though metastatic disease is the main cause of cancer-related death, little is known about patterns of metastatic spread in patients. In the current study, we describe a method to describe and model the complexity of recurrent disease progression in a well-described patient cohort. Understanding heterogeneity in recurrent disease and the ability to predict the underlying metastatic patterns in individual patients will eventually improve diagnostic accuracy, allow early detection of recurrences due to personalized surveillance and thus will increase the chances of successful treatment.
Data Availability
Data from the study are available on request
